MLMei Chin Lim

Mei Chin Lim

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mei Chin Lim has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A protocol for a systematic review with prospective individual patient data meta-analysis in EGFR mutant NSCLC with brain metastases to assess the effect of SRS + Osimertinib compared to Osimertinib alone: the STARLET collaboration

    by Kristy P Robledo, Shilo Lefresne, Yu Yang, Arjun Sahgal, Mark B Pinkham, Alan Nichol, Ross Andrew Soo, Ambika Parmar, Fiona Hegi-Johnson, Mark Doherty, et al.

    Background: Patients with advanced non-small-cell lung cancer (NSCLC) with activating mutations in the epidermal growth factor receptor ( EGFR ) gene are a heterogenous population who often develop brain metastases (BM). The optimal management of patients with asymptomatic brain metastases is unclear given the activity of newer generation targeted therapies in the central nervous system. We present a protocol for an individual patient data prospective meta-analysis (IPD-PMA) to evaluate whether the addition of stereotactic radiosurgery (SRS) before Osimertinib treatment will lead to better control of intracranial metastatic disease. This is a clinically relevant question that will inform practice. Methods: Randomised controlled trials (RCTs) will be eligible if they included: participants with BM arising from EGFR mutant NSCLC and suitable to receive Osimertinib both in the first- and second-line settings (P); comparisons of SRS followed by Osimertinib versus Osimertinib alone (I, C); and intracranial disease control included as an endpoint (O). Systematic searches of Medline (Ovid), Embase (Ovid), Cochrane Central Register of Controlled Trials (CENTRAL), CINAHL (EBSCO), PsychInfo, ClinicalTrials.gov and the World Health Organisation’s International Clinical Trials Registry Platform’s Search Portal will be undertaken. An IPD meta-analysis will be performed using methodologies recommended by the Cochrane Collaboration. The primary outcome is intra-cranial progression free survival, as determined by RANO-BM criteria. Secondary outcomes include overall survival, time to whole brain radiotherapy, quality of life and adverse events of special interest. Effect differences will be explored among pre-specified subgroups. Ethics and dissemination: Approved by each trials ethics committee. Results will be relevant to clinicians, researchers, policymakers and patients, and will be disseminated via publications, presentations and media releases. Prospero registration: CRD42022330532 Strengths and Limitations of this study: The use of an individual patient data (IPD) meta-analysis will give increased statistical power for the relative comparison of SRS followed by Osimertinib versus Osimertinib alone on intracranial progression-free survival. Such a meta-analysis will also enable the exploration of subgroups. Frequency of outcome assessment and outcome measures may be collected and reported differently across included trials, which may lead to some imprecision. Harmonisation of clinical trial protocols through prospective meta-analysis will address some of these limitations. A limitation of this study is that the searches will only be conducted until late 2023 and any studies that are registered after this time will not be included.

  • Clinical application of “black bone” imaging in paediatric craniofacial disorders

    by Xi Zhen Low, Mei Chin Lim, Vincent Nga, Gangadhara Sundar, Ai Peng Tan

    For decades, CT has been the primary imaging modality for the diagnosis and surveillance of paediatric craniofacial disorders. However, the deleterious effects of ionising radiation in the paediatric population are well established and remain an ongoing concern. This is especially so in the head and neck region, which has relatively poor soft tissue shielding with many radiosensitive organs. The development of “black bone” imaging utilising low flip angles and short echo time (TE) has shown considerable promise in alleviating the use of ionising radiation in many cases of craniofacial disorders. In this review article, we share our experience of utilising “black bone” sequence in children with craniofacial pathologies, ranging from traumatic injuries to craniosynostosis and focal osseous/fibro-osseous lesions such as fibrous dysplasia and Langerhans cell histiocytosis (LCH). A detailed discussion on the technical aspects of “black bone” sequence, including its potential pitfalls and limitations, will also be included.